
Over 25 years of clinical data support NB-UVB as one of the most effective treatments for psoriasis, atopic dermatitis, and vitiligo.1
Convenience makes the Zerigo Program easy to stick to, for better outcomes.
Length of time an average psoriasis patient treats with the Zerigo device per session.
From enrolling to starting treatment—so members start to see real results, fast.
“Great product and service. I can do my treatment on my own time and no need to go to a clinic. My Care Guide is very responsive and helpful, always in contact and doing follow up with me. Thank you!”
“It’s been one of the only things that has helped clear my psoriasis. I’m so happy that I finally found something that works for me!“
“Love the [Zerigo] system…I began noticing results within 6 weeks and it completely healed around the 3-month mark. I can finally leave my house embarrassment-free and make-up free again.”
“I get constant positive results on my skin. I’m a very happy customer.”
“Zerigo completely cleared my psoriasis for the first time in almost a decade. After about 3 months, I was completely clear from head to toe, I cannot thank Zerigo enough!”
“Love how the app tells me when it’s time to treat!”
“I have seen great results using this product in conjunction with my topical treatments.”
“Clear skin without psoriasis? It’s the best!”
1The Zerigo Health Phototherapy System is an ultraviolet-light-emitting medical device. It is intended for use in localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). The device can be used in the comfort of a patient’s home or in a physician’s office. Individual results may vary. U.S. federal law restricts this device to sale by or on the order of a physician.
2 Springer Dermatological Research; Adjunctive Treatment of Atopic Dermatitis with Novel At-Home Handheld Narrow-Band UVB Phototherapy
3 Journal of Drugs in Dermatology; The Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis.
4 BCN Digitized Enrollment report, April 2024